Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Arrowhead Pharmaceuticals Says It Initiated Phase 1/2a Study Of ARO-DM1 For Treatment Of Type 1 Myotonic Dystrophy, Company Adds ARO-DM1 Is Designed To Reduce Expression Of Dystrophia Myotonica Protein Kinase (DMPK) Gene In Muscle

Author: Benzinga Newsdesk | March 08, 2024 08:34am

Posted In: ARWR